Preventing LCK Activation in CAR T Cells Confers Treg Resistance but Requires 4-1bb Signaling for Them to Persist and Treat Solid Tumors in Non-Lymphodepleted Hosts

Clinical Cancer Research - United States
doi 10.1158/1078-0432.ccr-18-1211
Full Text
Abstract

Available in full text

Date
Authors
Publisher

American Association for Cancer Research (AACR)

Related search

4-1bb Signaling Beyond T Cells

Cellular and Molecular Immunology
Infectious DiseasesMedicineAllergyImmunology
2011English

Making CAR T Cells a Solid Option for Solid Tumors

Frontiers in Immunology
AllergyImmunology
2018English

CAR T Cells in Solid Tumors: Blueprints for Building Effective Therapies

Frontiers in Immunology
AllergyImmunology
2018English

CAR T-Cell Therapy for Solid Tumors?

Cancer Discovery
Oncology
2018English

CAR T Cells for Solid Tumors: New Strategies for Finding, Infiltrating, and Surviving in the Tumor Microenvironment

Frontiers in Immunology
AllergyImmunology
2019English

394. McSP-Chimeric Antigen Receptor (CAR)-Redirected T Cells Target Multiple Solid Tumors

Molecular Therapy
Molecular MedicineMolecular BiologyPharmacologyMedicineGeneticsDrug Discovery
2013English

LCK-Dependent Fyn Activation Requires C Terminus-Dependent Targeting of Kinase-Active LCK to Lipid Rafts

Journal of Biological Chemistry
BiochemistryCell BiologyMolecular Biology
2008English

Oncolytic Virus Expressing RANTES and IL-15 Enhances Function of CAR-modified T Cells in Solid Tumors

OncoImmunology
OncologyAllergyImmunology
2015English

CAR T Cells for Brain Tumors: Lessons Learned and Road Ahead

Immunological Reviews
AllergyImmunology
2019English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy